| Literature DB >> 9890007 |
Abstract
Entities:
Mesh:
Year: 1999 PMID: 9890007 PMCID: PMC7149316 DOI: 10.1016/s0065-3519(99)80006-8
Source DB: PubMed Journal: Adv Vet Med ISSN: 1093-975X
Fig. 1Schematic depicting the historical interactions between the laboratory diagnosis of infectious disease and the steps leading to corrective management.
Fig. 2Schematic depicting the current and future interactions between the laboratory testing of animals-at-risk to determine if preclinical infection has occurred, and the steps leading to preventive management.
ECOLOGY OF INFECTION IN RELATIONSHIP TO DETECTION OF INFECTION AND DIAGNOSIS OF DISEASE
| Ecology of infection | ||||||
|---|---|---|---|---|---|---|
| Transmissible agent | Infection rate (%) | Attack rate (%) | Mortality rate (%) | Detection of infection | Diagnosis of disease | Vaccine available |
| Prion induced disease (scrapie) | Unknown (variable) | IHC (biopsy) genetic typing | Clinical signs, histopath | No | ||
| Coronavirus induced disease (FIP) | 85 | 2 | 99 | Serology, PCR, genetic typing? | Clinical signs, histopath | Yes (40–80%) |
| Lentivirus induced disease (CAE) | 85 | 30 | <10 | Serology, PCR, genetic typing? | Clinical signs, histopath | No |
| Pestivirus induced disease (BVD) | 85 | 10 | <5 | Serology, PCR | Clinical signs, histopath, IHC | Yes (80–90%) |
| BVD-PI (immunotolerant) | 1–2 | 50 | 90 | PCR, VI | Clinical signs, histopath, IHC | Yes (variable) |
| Herpesvirus induced disease (EHV-1) | 85 | 10 | 5 | Serology, VI, PCR | Clinical signs, histopath, IHC | Yes (variable) |
Antemortem.
USDA-APHIS survey in progress.
Fig. 3Schematic depicting the conceptual view of infection rate, attack rate, and mortality rate. (a) An infection with a low infection rate, i.e., rabies virus, but a high mortality rate. (b) An infection with a high infection rate, i.e., caprine arthritis encephalitis virus, and a low mortality rate.
Fig. 4Schematic depicting the conceptual view of further analyses of the attack rate into (a) progressor and nonprogressor, and the mortality rate into lethal and nonlethal. (b) How CAE virus infection occurs in this scheme.
Fig. 5(a) Schematic depicting the differences between subclinical and clinical infections where infectious agents are detected (panel a). (b) The different levels of sensitivity of detection assays, with assay A being the most sensitive and assay E being the least sensitive.
FIVE KEY QUESTIONS TO ASK REGARDING INFECTIONS/DISEASES OF ANIMALS
Is the infection and/or disease of economic concern? Is the infection and/or disease of zoonotic concern? Where is the microbial agent when not causing disease (microbial ecology)? What are the contributing factors to the infection and/or disease process? What factors can animal owners/veterinarians/public health personnel control to minimize or eliminate the risk of infection/disease process? |
THE CONSEQUENCES OF THE INFECTION/DISEASE PROCESS ON THE ANIMAL
No sale Public health risk Early cull Regulatory quarantine Shedding of microbial agent to susceptible animals in the population Segregation of animal Euthanasia of animal(s) |
WHERE WE SHOULD BE GOING WITH VETERINARY DIAGNOSTICS
Assays to monitor immune function (immune competence)
Foal check Calf failure of passive transfer Llama/alpaca immunoglobulin status CMI response Assays to monitor genetic resistance/genetic susceptibility
Cellular receptors Cellular oncogenes Cellular prion proteins Assays to monitor infections
In the environment In asymptomatic vectors (potential transmissibility) In asymptomatic carriers (potential shedders) Assays to diagnose disease
Prognosis Monitor response to treatment via cytokines (IL-2, IL-4, etc.) Assays to track emerging infections
Culture Conserved PCR Disease potential Develop new detection assays Develop new vaccines |